Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged SCOTUS
The Amgen v. Sanofi decision will encourage more biotech innovation—not the other way around.

I have blogged about the Amgen v. Sanofi case several times, and the case has been summarized in my prior posts andelsewhere.  The case pitted two competing PCSK9-inhibitors against one another, and after several years, resulted in cancelling broad patents covering the new class of antibodies.  Whenever there is any case that cancels patents within the pharmaceutical or biotech space, the common knee-jerk retort from some commentators is that the decision will suppress innovation, chill R&D and discourage any investment in life-saving medicine.  In this case, the opposite is true.

Read More